0001144204-13-031657.txt : 20130524 0001144204-13-031657.hdr.sgml : 20130524 20130524201614 ACCESSION NUMBER: 0001144204-13-031657 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130522 FILED AS OF DATE: 20130524 DATE AS OF CHANGE: 20130524 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wolfenson Barry CENTRAL INDEX KEY: 0001354818 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-13070 FILM NUMBER: 13873225 MAIL ADDRESS: STREET 1: DERMA SCIENCES, INC. STREET 2: 214 CARNEGIE CENTER, SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: DERMA SCIENCES, INC. CENTRAL INDEX KEY: 0000892160 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 232328753 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 214 CARNEGIE CENTER, SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6095144744 MAIL ADDRESS: STREET 1: 214 CARNEGIE CENTER, SUITE 300 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DERMA SCIENCES INC DATE OF NAME CHANGE: 19940513 4 1 v346213_form4.xml OWNERSHIP DOCUMENT X0306 4 2013-05-22 0 0000892160 DERMA SCIENCES, INC. DSCI 0001354818 Wolfenson Barry DERMA SCIENCES, INC. 214 CARNEGIE CENTER, SUITE 300 PRINCETON NJ 08540 0 1 0 0 SEE REMARKS Stock Option (right to buy) 11.97 2013-05-22 4 A 0 16000 0 A 2013-05-22 2023-02-13 Common Stock 16000 16000 D The option grant was approved by the compensation committee of the issuer's board of directors on February 13, 2013, subject to stockholder approval of an amendment to the issuer's equity incentive plan to increase the shares available for issuance thereunder. The issuer's stockholders approved the amendment on May 22, 2013. The options, granted pursuant to the issuer's equity incentive plan, vested as to 25% on the grant date, subject to stockholder approval of the amendment to the issuer's equity incentive plan which was obtained on May 22, 2013, and will vest as to an additional 25% on February 13 of 2014, 2015 and 2016. Group President, Advanced Wound Care & Pharmaceutical Development /s/ Barry J. Wolfenson 2013-05-24